Soligenix   Report issue

For profit Phase 2 Phase 3
Founded: Princeton NJ United States (1987)
Status: Left NME R&D (2017)

Organization Overview

First Clinical Trial
2009
NCT00926575
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Soligenix

Active Ingredients

Drugs in Phase 3 Trials (3)

beclomethasone (vanceril) (3 trials)

dusquetide (2 trials)

hypericin (sgx301) (5 trials)

Drugs in Phase 2 Trials (1)

mechlorethamine (mustargen) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Enteritis (Phase 2)

Graft vs Host Disease (Phase 3)

Lymphoma (Phase 3)

Lymphoma, T-Cell (Phase 3)

Lymphoma, T-Cell, Cutaneous (Phase 3)

Mucositis (Phase 3)

Mycosis Fungoides (Phase 3)

Stomatitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 4